Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: A European model based on the CLARITY and COMMIT trials

Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy

“…Most of the models used incremental cost per life-years gained as their primary outcome [13][14][15][18][19][20]22,[24][25][26][27][28] , although some of these models also included incremental cost per quality-adjusted life-year (QALY) gained in a sensitivity or secondary analysis 15,19,20,22,28 . Other models used incremental cost per QALY gained as the primary outcome measure 16,17,21,23 .…”

“…The Badia and colleagues 13 article also performed a 1-year analysis using a decision-tree structure. Two articles used a Markov structure starting from the end of the first year but modelled the first year using a decision-tree structure 22,23 . Finally, five articles used a decision-tree structure for the first year and then extrapolated beyond this time period by estimating life-expectancy gains attributable to the pattern of clinical events in the first year observed for each treatment arm [24][25][26][27][28] .…”

An economic model to assess the cost-benefit of BNCT

“…Willingness to pay (WTP) has more recently been used in conjunction with QALYs in assessing net benefits of medical interventions (Berg et al, 2007;Borgstrom et al, 2006;Deutsch et al, 2006;Fox et al, 2007;Hurley et al, 2007;Lyman et al, 2007;Quigley et al, 2008;Remak et al, 2005;Rubenstein and Inadomi, 2006;Rutten-van Molken et al, 2007;Steuten et al, 2007;Thompson Coon et al, 2007). However, critical concerns have been raised both concerning the validity of WTP for a QALY, and the use of QALYs per se.…”

Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: When does the risk outweigh the benefit?

“…Although the major clinical trials that have examined the efficacy of dual antiplatelet therapy in the management of post-STEMI patients have utilized treatment durations of no more than one month [11,17], dual antiplatelet therapy with clopidogrel and aspirin for periods of up to one year was estimated to be highly cost-effective (incremental costeffectiveness ratio, €2772-€4144 per life-year gained) [27].…”